Skip to main content
Fig. 7 | Biomarker Research

Fig. 7

From: Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel

Fig. 7

Differential protein levels in metastatic lymph node and lung biopsies for the subset of patients treated with pembrolizumab following PIKTOR and cisplatin nab paclitaxel. Pre-treatment biopsies were obtained prior to the study treatments. Post-PIKTOR biopsies were obtained following PIKTOR treatment, but prior to cisplatin nab paclitaxel and pembrolizumab. (A) Glucocorticoid receptor protein levels were higher in biopsies obtained prior to PIKTOR, cisplatin nab paclitaxel, and pembrolizumab for the subset of patients that had a durable response to pembrolizumab. (B) Proteins involved in DNA damage repair, proliferation, immune cell activity, and chemotaxis were significantly lower in post-PIKTOR treatment biopsies for patients that responded to pembrolizumab compared to non-responders. Samples 1, 6, 8, and 4 were lymph node metastasis. Sample 5 and 9 were lung metastases

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us